Lineage Cell Therapeutics. has been granted a patent for a method to generate human retinal pigment epithelium (RPE) cells. The method involves culturing human pluripotent stem cells with specific media conditions, resulting in RPE cells that co-express PMEL17 and CRALBP, with high trans-epithelial electrical resistance. GlobalData’s report on Lineage Cell Therapeutics gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Lineage Cell Therapeutics, Embryonic stem cell culturing was a key innovation area identified from patents. Lineage Cell Therapeutics's grant share as of June 2024 was 41%. Grant share is based on the ratio of number of grants to total number of patents.
Method for generating human retinal pigment epithelium cells
The patent US11987810B2 outlines a method for generating retinal pigment epithelium (RPE) cells from human pluripotent stem cells. The process involves several key steps, beginning with the culturing of stem cells in a medium containing nicotinamide, but devoid of Activin A, for a period of one to three weeks to produce differentiating cells. These cells are then cultured for an additional one to four weeks in a medium that includes both Activin A and nicotinamide to further differentiate them towards the RPE lineage. The final stage involves culturing these cells in a nicotinamide medium, again without Activin A, for up to four weeks under low oxygen conditions (less than 10% atmospheric oxygen). The resulting RPE cells are characterized by the co-expression of premelanosome protein (PMEL17) and cellular retinaldehyde binding protein (CRALBP), with at least 80% of the cells exhibiting this co-expression after the differentiation process.
Further claims in the patent detail variations and enhancements to the method. For instance, it specifies that the RPE cells can be expanded in suspension or on an extracellular matrix, and that the initial culturing can occur under non-adherent conditions to form cell clusters. The patent also allows for the selection of polygonal cells post-differentiation and mentions the potential use of embryonic stem cells propagated in specific media prior to the differentiation steps. Additionally, it notes that the atmospheric oxygen level can be adjusted during the culturing process, and emphasizes the importance of achieving high co-expression rates of PMEL17 and CRALBP, with claims stating that at least 95% of the RPE cells should co-express these proteins after expansion.
To know more about GlobalData’s detailed insights on Lineage Cell Therapeutics, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies across the world’s largest industries.
